Subhendu Mukherjee

Bengaluru, KA, India

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Author Correction: Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer.

Author Correction: Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer.

Journal: Nature

Published: April 22, 2024

Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.

Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: April 01, 2024

Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.

Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.

Journal: bioRxiv : the preprint server for biology

Published: March 11, 2024

Design, synthesis, and biological evaluation of phenyl thiazole-based AR-V7 degraders.

Design, synthesis, and biological evaluation of phenyl thiazole-based AR-V7 degraders.

Journal: Bioorganic & medicinal chemistry letters

Published: August 04, 2021

Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer.

Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer.

Journal: Nature

Published: March 17, 2021

Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies.

Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies.

Journal: ACS medicinal chemistry letters

Published: May 13, 2020

ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity.

ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity.

Journal: Molecular cancer therapeutics

Published: March 09, 2018

Structure-guided discovery of 2-aryl/pyridin-2-yl-1H-indole derivatives as potent and selective hepsin inhibitors.

Structure-guided discovery of 2-aryl/pyridin-2-yl-1H-indole derivatives as potent and selective hepsin inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: July 07, 2015

Discovery of O-(3-carbamimidoylphenyl)-l-serine amides as matriptase inhibitors using a fragment-linking approach.

Discovery of O-(3-carbamimidoylphenyl)-l-serine amides as matriptase inhibitors using a fragment-linking approach.

Journal: Bioorganic & medicinal chemistry letters

Published: September 02, 2014

3-alkoxy-pyrrolo[1,2-b]pyrazolines as selective androgen receptor modulators with ideal physicochemical properties for transdermal administration.

3-alkoxy-pyrrolo[1,2-b]pyrazolines as selective androgen receptor modulators with ideal physicochemical properties for transdermal administration.

Journal: Journal of medicinal chemistry

Published: August 15, 2014

Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacy.

Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacy.

Journal: Bioorganic & medicinal chemistry

Published: March 03, 2014

Discovery of Pyridyl Bis(oxy)dibenzimidamide Derivatives as Selective Matriptase Inhibitors.

Discovery of Pyridyl Bis(oxy)dibenzimidamide Derivatives as Selective Matriptase Inhibitors.

Journal: ACS medicinal chemistry letters

Published: June 17, 2013

Showing 1-12 of 12

Last Updated: 09/26/2026